Biopharmaceutical firm Neoleukin Therapeutics Inc (NASDAQ: NLTX) received a clinical hold letter from the US Food and Drug Administration (FDA) relating to its Investigational New Drug (IND) Application to begin a Phase 1 clinical trial of its immunotherapeutic candidate, NL-201 the company said on Friday.
Neoleukin shares fell over 20% on the news. They are currently sitting at the $13.88 level, down 12.04%.
A clinical hold letter is issued by the FDA to suspend or delay a clinical trial or investigation. Once Neoleukin has submitted a response to the FDA, they will then evaluate the response and decide whether to lift the hold.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
The FDA told the company it needs to develop a new assay that more precisely measures the amount of protein being administered and demonstrate with this assay that dose and administration procedures will accurately deliver the intended dose of NL-201.
“We will work diligently to address the FDA’s questions as quickly as possible,” said Jonathan Drachman, CEO of Neoleukin.
“We believe that we will be able to develop the requested assay and respond within the next several months,” added Drachman.
